A Pilot Phase I Randomized Study to evaluate Innate Immune Activation predictors of sustained viral control in HIV-Infected Adults Undergoing a Brief Analytical Treatment Interruption after the administration of Pegylated Interferon Alpha 2b in Combination with Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074

Our pilot study will evaluate whether the activation of antiviral innate mechanisms by administration of Pegylated Interferon alpha 2b (peg-IFN-2b) when combined with two broadly neutralizing antibodies (3BNC117 and 10-1074) in HIV positive participants with well controlled viral replication can result in viral control in the absence of ART or immune based therapy during a monitored analytical treatment interruption.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Medical Research
• Age: - 99 Years
• Gender: All